Roche Upbeat On Ocrevus Despite Consensus Miss
COVID-19 And Competition Slows Growth
Executive Summary
Fewer patients with multiple sclerosis are switching treatment during the pandemic but despite that, and the arrival of competition from Novartis's Kesimpta, Roche insists Ocrevus growth remains strong.
You may also be interested in...
Novartis Wins EU Thumbs Up for MS Treatment
Kesimpta could become the first and only self-administered, targeted B-cell therapy for patients in Europe with relapsing forms of multiple sclerosis.
Novartis MS Drug Kesimpta Quick Out Of The Blocks
Kesimpta is a treatment option for multiple sclerosis patients "that doesn't need compromise, the trade-off between high efficacy and high treatment burden," Novartis neuroscience chief Norman Putzki tells Scrip.
Bayer Ponders Road Less Traveled And Trip Savings In Pandemic
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports